Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Progressis** is an inactivated vaccine for pigs (sows and gilts) developed to reduce reproductive disorders caused by Porcine Reproductive and Respiratory Syndrome (PRRS) virus, specifically European strains, in contaminated environments. It contains inactivated PRRS virus (P120 strain) in an emulsion for injection and works by inducing both cell-mediated immunity (CMI), including interferon-gamma secreting cells, and humoral immunity, such as ELISA and seroneutralizing antibodies, against a broad range of type 1 and type 2 PRRS field strains. The vaccine boosts immunity when used in dual technology prime-boost (DTPB) regimens with live vaccines, reducing early farrowings, stillbirths, and viraemic piglets at weaning; it is safe for use during pregnancy and lactation with no risk of reversion to virulence or virus spread.[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Progressis.